Takeda files reply in support of decertifying class in US Amitiza antitrust case
( July 10, 2026, 21:21 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals filed a reply in support of its motion to decertify a class of direct purchasers accusing it of delaying a generic version of the drug Amitiza. “DPPs have no persuasive response to two fundamental problems laid bare at trial: their damages model does not measure the injury they urged at certification, and it depends on statistical averages that Dr. Leffler declared categorically insufficient to measure individual class member damages,” Takeda argued.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.